tailieunhanh - FACING THE REALITY OF DRUG-RESISTANT TUBERCULOSIS: CHALLENGES AND POTENTIAL SOLUTIONS IN INDIA

The workshop summarized in this volume was the third international meeting in a series sponsored by the Forum on Drug Discovery, Development, and Translation of the Institute of Medicine (IOM) to gather information from experts around the world on the threat of drugresistant tuberculosis (TB) and how it can be addressed. The workshop was held April 18-19 and 21, 2011, in New Delhi, India, in collaboration with the Indian National Science Academy (INSA) and the Indian Council of Medical Research (ICMR) | FACING THE REALITY OF DRUG-RESISTANT TUBERCULOSIS CHALLENGES AND POTENTIAL SOLUTIONS IN INDIA INSTITUTE OF MEDICINE THE NATIONAL ACADEMIES PRESS Facing the Reality of Drug-Resistant Tuberculosis Challenges and Potential Solutions in India Summary of a Joint Workshop by the Institute of Medicine the Indian Nation FACING THE REALITY OF DRUG-RESISTANT TUBERCULOSIS CHALLENGES AND POTENTIAL SOLUTIONS IN INDIA SUMMARY OF A JOINT WORKSHOP BY THE INSTITUTE OF MEDICINE INDIAN NATIONAL SCIENCE ACADEMY and INDIAN COUNCIL OF MEDICAL RESEARCH Steve Olson Rebecca A. English Rita S. Guenther and Anne B. Claiborne Rapporteurs Forum on Drug Discovery Development and Translation Board on Health Sciences Policy INSTITUTE OF MEDICINE OF THE NATIONAL ACADEMIES THE NATIONAL ACADEMIES PRESS Washington . Copyright National Academy of Sciences. All rights reserved. Facing the Reality of Drug-Resistant Tuberculosis Challenges and Potential Solutions in India Summary of a Joint Workshop by the Institute of Medicine the Indian Nation THE NATIONAL ACADEMIES PRESS 500 Fifth Street NW Washington DC 20001 NOTICE The project that is the subject of this report was approved by the Governing Board of the National Research Council whose members are drawn from the councils of the National Academy of Sciences the National Academy of Engineering and the Institute of Medicine. This study was supported by contracts between the National Academy of Sciences and Department of Health and Human Services Contract Nos. N01-OD-4-2139 and 223001003T . State Department S-LMAQM-08-GR-071 American Society for Microbiology Amgen Inc. Association of American Medical Colleges Bristol-Myers Squibb Burroughs Wellcome Fund Celtic Therapeutics LLLP Critical Path Institute Doris Duke Charitable Foundation Eli Lilly Co. FasterCures Foundation for the NIH Friends of Cancer Research GlaxoSmithKline Johnson Johnson Merck Co. Inc. Novartis Pharmaceuticals Corporation and Pfizer Inc. Any opinions findings .